Helse Forde HF
- Address
- lock Available on a paid plan
Musculoskeletal Diseases
Research at Helse Forde HF focuses on improving care for patients with rheumatoid arthritis by exploring advanced monitoring strategies.
- Proactive therapeutic drug monitoring
- Subcutaneous TNF inhibitor use
- Flare prevention and sustained disease control
- Patient‑reported outcome measures
The goal is to enhance treatment effectiveness and quality of life through personalized dosing and early detection of loss of response.
Neoplasms
The department is advancing precision medicine for cancer by matching targeted therapies to specific genomic or protein expression variants.
- Genomic profiling of advanced malignancies
- Identification of drug‑sensitive mutations
- Evaluation of safety and anti‑tumour activity
- Integration of real‑world evidence into treatment pathways
This work aims to broaden access to effective, individualized cancer treatments across Norway.
Nervous System Diseases
Studies address the needs of people living with multiple sclerosis by testing the safety of adding TAF to established natalizumab therapy.
- Combination safety assessment
- Immunomodulatory effects of add‑on therapy
- Monitoring of neurological outcomes
- Long‑term tolerability in active disease
Findings are intended to expand therapeutic options for patients with aggressive disease activity.
Otorhinolaryngologic Diseases
Clinical work evaluates whether hyperbaric oxygen therapy can improve recovery in idiopathic sudden sensorineural hearing loss when added to standard treatment.
- Hearing restoration outcomes
- Optimal timing and duration of HBOT
- Impact on daily communication abilities
- Safety and patient tolerance
The initiative seeks to provide faster, more effective interventions for acute ENT emergencies in the Foerde region.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 51 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Oslo University Hospital HF2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helse Forde HF
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, phase II, open-label, multicenter study investigating efficacy and safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer | Vestre Viken HF | Phase II | Not Recruiting | Aug 2022 | Sep 2024 |
IMP list
lock Showing 1 of 51 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 3 | Unknown | 2021-04-01 | 2024-09-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.